[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601521":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":29,"id":40,"slug":10,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":10},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"UC patients accept therapy of biologics",null,[12],"Diagnostic Test: fecal calprotectin",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","fecal calprotectin","patients will accpet test of FC combine FIT",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Yan Zhang, M.D","CONTACT","+86 18560089821","qlzhangyan@sdu.edu.cn",{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","zhangyan","M.D",[30,32,34,36,38],{"name":31,"class":6},"Qilu Hospital of Shandong University (Qingdao)",{"name":33,"class":6},"Dezhou Hospital Qilu Hospital of Shandong University",{"name":35,"class":6},"Weihai Municipal Hospital",{"name":37,"class":6},"Liaocheng People's Hospital",{"name":39,"class":6},"Jining First People's Hospital","100601521",false,"NCT07111572","Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis","Dynamic Changes of Fecal Calprotectin and Fecal Immunochemical Test for Early Prediction of Biologic Treatment Efficacy in Ulcerative Colitis: A Multicenter, Prospective Cohort Study","FORESEE-UC","Inclusion Criteria:\\*\\*\n\n* Age 18-75 years, UC diagnosis with endoscopic Mayo score (MES) ≥2\n* Moderate-to-severe activity (Full Mayo Score ≥6)\n* Initiating vedolizumab or infliximab within 7 days after baseline\n* Biologic-naïve or prior exposure to only one TNF-α inhibitor\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Pregnancy\u002Flactation\n* Contraindications to biologics (e.g., active TB, severe infection)\n* Experimental drug use within 4 weeks prior to baseline","ALL","18 Years","75 Years",{"count":51,"type":52},100,"ESTIMATED","OBSERVATIONAL","This multicenter prospective cohort aims to evaluate whether combined changes in fecal calprotectin (FC) and fecal immunochemical test (FIT) at \\*\\*Week 2 and Week 4\\*\\* after initiating biologic therapy (vedolizumab or infliximab) can predict clinical response at \\*\\*Week 14\\*\\* and mucosal healing at \\*\\*Week 52\\*\\* in moderate-to-severe ulcerative colitis (UC) patients. Primary outcome: clinical remission rate at Week 14.",[56,57,58],"Ulcerative Colitis (UC)","Fecal Calprotetin","FIT",[60,16,58],"UC","NOT_YET_RECRUITING","2025-08-01",{"date":64,"type":65},"2025-08-08","ACTUAL",{"date":62,"type":52},{"date":68,"type":52},"2026-12-01",{"name":5,"class":6}]